Illumina president and CEO Francis deSouza (Photo by Kevin Dietsch/Getty Images)

EU set to launch full-scale in­ves­ti­ga­tion in­to Grail-Il­lu­mi­na deal amid an­titrust con­cerns — re­port

The pro­posed $8 bil­lion merg­er be­tween liq­uid biop­sy firm Grail and can­cer blood screen­ing gi­ant Il­lu­mi­na has met with noth­ing but flack since it was first an­nounced in Sep­tem­ber. Af­ter hit­ting waves in the US ear­li­er this year, the pact is now fac­ing a po­ten­tial­ly dev­as­tat­ing set­back in the EU as well.

The EU is pre­pared to launch a full-scale probe in­to a pend­ing merg­er be­tween Grail and Il­lu­mi­na that has evolved in­to Ex­hib­it A for in­ter­na­tion­al an­titrust ad­vo­cates’ case against non­com­pet­i­tive phar­ma M&A, sources close to the deal told Reuters.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.